Explore how chemotherapy causes peripheral neuropathy in 40% of cancer patients. Learn about the risk factors and the need ...

The CHMP issued a positive opinion on the once-monthly RNA-targeting treatment at its October meeting, putting it on course to become the first drug for ATTR polyneuropathy in the EU that can be ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around four in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

Under this condition, which can result from traumatic injuries, infections, metabolic problems, or could be inherited due to ...

and other medications you take. By sharing this information with them, you may help prevent possible interactions. If you have questions about drug interactions that may affect you, ask your ...

BC, CNM, RNFA, spoke about the oncology nurse’s and APP’s roles in managing chemotherapy-induced peripheral neuropathy in ...

The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...

Medications are the mainstay of treatment for multiple sclerosis (MS). Many of them are used to block the immune system's attack on the nerves and slow or prevent progression and relapses (flare-ups) ...